Progress in the Clinical Application of Novel Biomarkers for the Diagnosis of ACPA-Negative Rheumatoid Arthritis
10.3969/j.issn.1671-7414.2025.03.039
- VernacularTitle:ACPA阴性类风湿关节炎诊断的新型生物标志物临床应用研究进展
- Author:
Chunhua CAO
1
;
Xiangren A
;
Xiaoqin LUO
Author Information
1. 青海大学,西宁 810001;青海省人民医院医学检验科,西宁 810007
- Publication Type:Journal Article
- Keywords:
rheumatoid arthritis;
anti-citrullinated protein antibody negative;
novel biomarkers
- From:
Journal of Modern Laboratory Medicine
2025;40(3):208-212
- CountryChina
- Language:Chinese
-
Abstract:
Rheumatoid arthritis(RA)is a chronic erosive joint inflammation as the main clinical manifestation of autoimmune disease.Currently,commonly used laboratory diagnostic indicators include rheumatoid factor(RF),anti-citrullinated protein antibody(ACPA),erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),etc.Among them,ACPA can be found in patients'serum at an early stage and has a higher diagnostic value.However,nearly one-third of RA patients are still ACPA-negative,and there is a lack of effective diagnostic markers.Therefore,it is of great significance to explore new biomarkers for the diagnosis of serum ACPA-negative RA patients and their clinical application value for early diagnosis and treatment.In recent years,there has been an increasing number of studies on diagnostic markers for ACPA-negative RA,mainly in the areas of proteomics,immune mechanisms,genetic inheritance and autoantibody production,and a number of new autoantibodies and proteins with relative specificity have been identified.This article reviews the value of the clinical application of these new autoantibodies and proteins in the diagnosis of ACPA-negative RA and their outlook,thus providing some reference value for the early diagnosis of the disease.
